Page 4 - Allurion Program News Today

NATICK, Mass.--(BUSINESS WIRE)--Aug 28, 2023--

Serial healthcare entrepreneur Douglas Hudson appointed to Board of Directors Tomer Stavitsky joins as VP of Corporate Development to lead M&A strategy focused on Artificial Intelligence ...

Allurion Technologies, Inc. and Compute Health Acquisition Corp. Announce Updated Terms to Warrant Agreement Amendment Warrant Holder Meeting to Take Place on...

NATICK, Mass. & WILMINGTON, Del.--(BUSINESS WIRE)--Jul 23, 2023--

The combination of the worlds first and only procedure less swallowable gastric balloon--which is placed without surgery, endoscopy, or anaesthesia and naturally passes out of the body after approximately 16 weeks--and the commonly prescribed anti-obesity drug liraglutide is a safe and effective way to boost weight loss.

Combination therapy led to nearly 19% weight loss at approximately 8 months Allurion, a company dedicated to ending obesity, today announced results from a new study that will be presented at the

Allurion has developed a small capsule that fills with water to create a gastric balloon after it settles in the stomach, offering a weight-loss alternative.

A combination of a swallowable Allurion gastric balloon and liraglutide delivers higher weight loss (around 19% after mean 4 months) than use of separate treatments.

Italy: An international multi-centre study has shown that combining the swallowable gastric balloon and the anti-obesity drug liraglutide is a safe and effective way to boost weight loss. The study is...

Researchers discovered a new treatment for overweight and obesity that combines the world's first and only procedureless swallowable gastric balloon--which is placed without surgery, endoscopy, or anaesthesia and naturally passes out of the body after approximately 16 weeks and the commonly prescribed anti-obesity drug liraglutide is a safe and effective way to boost weight loss.